Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed/refractory multiple myeloma
Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed/refractory multiple myeloma
复制标题
治疗前血清白细胞介素 6 水平可预测复发/难治性多发性骨髓瘤中卡非佐米诱导的高血压
DOI：
10.1080/10428194.2022.2038373
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Kuroda J
中科院分区：
文献类型：
--
作者：
Muramatsu A;Kobayashi T;Kawaji-Kanayama T;Uchiyama H;Sasaki N;Uoshima N;Nakao M;Takahashi R;Shimura K;Kaneko H;Kiyota M;Wada K;Chinen Y;Hirakawa K;Fuchida S;Shimazaki C;Mizutani S;Tsukamoto T;Shimura Y;Taniwaki M;Teramukai S;Kuroda J
卡非佐米（CFZ）是复发性/难治性多发性骨髓瘤（RRMM）的有效联合治疗;然而，心血管不良事件（CVAE）已被证明是使用CFZ的主要治疗障碍。沿着我们由京都临床血液学研究组进行的关于基于CFZ治疗的疗效和安全性的多机构前瞻性观察性研究（UMIN 000025108），我们在此对50例RRMM患者的CFZ相关CVAE进行了专门分析。我们分析了CFZ相关CVAE与预先计划的检查之间的相关性，包括患者的背景、心电图结果、超声心动图结果和18种潜在候选生物标志物的血清/血浆水平。常见的CVAE为高血压（42%）、心律失常（14%）和校正QT间期延长（10%），但未发生严重CVAE。治疗前血清白细胞介素-6水平被确定为CFZ相关高血压的显著危险因素。这项研究显示高血压是最常见的CFZ相关CVAE，并表明基线血清白细胞介素-6是CFZ诱导的高血压的有用预测因子。
Carfilzomib (CFZ) constitutes powerful combinatory therapy for relapsed/refractory multiple myeloma (RRMM); however, cardiovascular adverse events (CVAEs) have been shown as major treatment obstacles with the use of CFZ. Along with our multi-institutional prospective observational study by the Kyoto Clinical Hematology Study Group on the efficacy and safety of CFZ-based treatments (UMIN000025108), we here performed an ad hoc analysis of CFZ-related CVAEs in 50 patients with RRMM. We analyzed the association between CFZ-related CVAEs and pre-planned examinations, including patients’ background, electrocardiographic findings, echocardiographic findings, and serum/plasma levels of 18 potential candidate biomarkers. The common CVAEs were hypertension (42%), arrhythmia (14%), and prolongation of QT corrected interval (10%), whereas no serious CVAEs occurred. The pretreatment serum level of interleukin-6 was identified as a significant risk factor for CFZ-related hypertension. This study revealed hypertension as the most frequent CFZ-related CVAE and suggested that baseline serum interleukin-6 is a useful predictor for CFZ-induced hypertension.
登录
查看更多内容
DOI：
10.1001/jama.1996.03530440037034
发表时间：
1996-05
期刊：
JAMA
影响因子：
--
作者：
Daniel Levy;M. Larson;R. Vasan;W. Kannel
通讯作者：
Daniel Levy;M. Larson;R. Vasan;W. Kannel
影响因子：
51.1
作者：
Moreau, Philippe;Mateos, Maria-Victoria;Stewart, A. Keith
通讯作者：
Stewart, A. Keith
DOI：
10.1002/cnr2.1476
发表时间：
2022-03
期刊：
Cancer reports (Hoboken, N.J.)
影响因子：
--
作者：
Kawaji-Kanayama Y;Kobayashi T;Muramatsu A;Uchiyama H;Sasaki N;Uoshima N;Nakao M;Takahashi R;Shimura K;Kaneko H;Kiyota M;Wada K;Chinen Y;Hirakawa K;Fuchida SI;Shimazaki C;Matsumura-Kimoto Y;Mizutani S;Tsukamoto T;Shimura Y;Horiike S;Taniwaki M;Kuroda J;Kyoto Clinical Hematology Study Group (KOTOSG) Investigators
通讯作者：
Kyoto Clinical Hematology Study Group (KOTOSG) Investigators
影响因子：
158.5
作者：
Wang, Thomas J.;Gona, Philimon;Vasan, Ramachandran S.
通讯作者：
Vasan, Ramachandran S.
影响因子：
20.3
作者：
Kuhn, Deborah J.;Chen, Qing;Orlowski, Robert Z.
通讯作者：
Orlowski, Robert Z.